ArticleLeukemia2016

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

D Sommermeyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.